Telix Pharmaceuticals LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
SCHEDULE 13G: Telix Pharmaceuticals: Dr. Christian Behrenbruch and Family Trust Disclose 6.97% Passive Stake
Dr. Christian Behrenbruch, along with Elk River Holdings Pty Ltd, has disclosed a combined beneficial ownership of 6.97% of Telix Pharmaceuticals Ltd's ordinary shares, primarily held through a family trust, as a passive investment.
NASDAQ
SCHEDULE 13G: German Investor Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft Disclose 6.78% Stake in Telix Pharmaceuticals
Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H. have jointly reported a beneficial ownership of 6.78% in Telix Pharmaceuticals Ltd, totaling 22,675,000 ordinary shares, as of November 12, 2024.